Toronto, Canada, July 27, 2009 - For Immediate Release
Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today that experienced medical device executive, Arthur L. Rosenthal Ph.D., has been appointed to its Board of Directors.
Dr. Rosenthal is currently CEO of Cappella, Inc., a medical device company focused on coronary artery disease. He has previously served as Chairman and CEO of Labcoat Ltd. (Galway, Ireland), Senior Vice President and Chief Scientific Officer of Boston Scientific Corporation, VP of Research & Development for Johnson & Johnson Medical and VP Research & Development at CR Bard. Dr. Rosenthal received his Ph.D. in Biochemistry from the University of Massachusetts.
“I have been impressed with the Interface Biologics technology and the product applications across a broad range of clinical disciplines” commented Dr. Rosenthal. “I look forward to sharing my medical device industry experience with IBI as they move toward commercialization.”
“We are extremely pleased to have a seasoned executive of Art’s caliber join our Board of Directors. His scientific background coupled with his management experience in both early stage and established medical device manufacturers will provide invaluable insights for our company” said Thomas P. Reeves, President and CEO, Interface Biologics.
About Interface Biologics Inc.
Interface Biologics develops technologies that work at the molecular level of the patient-device interface to enhance the safety and effectiveness of implantable medical devices through inhibition of thrombosis, infection control and unique, programmable delivery of pharmaceuticals and biologics. Interface has three product families: Endexo? Anti-thrombogenic Additives, Epidel? Anti-infective Polymers and Kinesyx? Bioactive Oligomers, all of which have applications across a broad spectrum of implantable medical devices.
FOR FURTHER INFORMATION PLEASE CONTACT:
Partner, Hageman Communications